Testing radioimmunotherapy combinations for lung cancer with metastases
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial explores whether combining radiation therapy with immunotherapy can trigger an immune response that shrinks tumors throughout the body (abscopal effect) in people with non-small cell lung cancer that has spread to 3 to 6 other sites. It tests different patterns of these treatments to see which works best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer, confirmed by a tissue sample.
- Your cancer has spread to 3 to 6 other spots in the body (not counting the main tumor).
- If you have had brain metastases, they are stable and not causing problems.
- Your tumor does not have certain gene changes (like EGFR, ALK, ROS, BRAF, MET, or RET).
- You are between 18 and 75 years old and have a good daily function level (ECOG score of 0 or 1).
- Your doctor expects you to live at least 3 more months, and you are able to have both immunotherapy and radiation therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation and immunotherapy to see if it can make the immune system attack cancer throughout the body in people with advanced lung cancer that has spread to many places. It's for those whose cancer does not have certain genetic changes and who have not had uncontrolled brain metastases.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
This trial tests whether adding radiotherapy to immunotherapy and chemotherapy can help people whose lung cancer has spread to the liver and who have already tried standard treatments. It aims to see if this combination is safe and works better at shrinking tumors.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a new combination of treatments for advanced non-small cell lung cancer (NSCLC) that has not been treated before. It combines a type of immunotherapy (envafolimab) with a drug that may slow blood vessel growth (endostar) and a special type of radiation therapy (SRT). This may help shrink tumors and control the cancer for a longer time.
This trial tests a combination of a personalized cancer vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation therapy for people with advanced non-small cell lung cancer that has gotten worse after at least two prior treatments. The goal is to see if this approach can help shrink tumors or slow cancer growth.
Hear when a new NSCLC Stage IV Without EGFR/ALK Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.